Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW642444M for 14 days · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GW642444M 25mcg | EXPERIMENTAL | In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg. |
| GW642444M 50mcg | EXPERIMENTAL | Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1. |
| GW642444M 100mcg | EXPERIMENTAL | In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg. |
| GW642444M 200mcg | EXPERIMENTAL | Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2. |
| GW642444M 400mcg | EXPERIMENTAL | Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3. |
| Name | Type | Description |
|---|---|---|
| GW642444M for 14 days | DRUG | M salt |
Inclusion criteria: * healthy males and females (of non-childbearing potential) aged 18-55 * body weight \>50kg with BMI 19-29.9 kg/m2 * normal ECG recording * non-smoker Exclusion criteria: * high blood pressure (above 140/90 mmHg) * pulse outside range 45 - 90 bpm * history of breathing problem...
GW642444M is an investigational small molecule being studied for the treatment of chronic obstructive pulmonary disease (COPD). It is in Phase 1 clinical development, with one completed trial evaluating its safety, blood levels, and effects in healthy volunteers.
GW642444M is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company conducted a Phase 1 clinical trial of the drug in the United Kingdom.
GW642444M is in Phase 1 clinical development. The drug is investigational and not yet approved. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
GW642444M has one completed clinical trial, registered under NCT00469040, titled "Safety, Blood Levels and Effects of GW642444." This Phase 1 study enrolled 36 participants in the United Kingdom, including healthy volunteers aged 18 years and older.
GW642444M is the drug name used in the clinical trial record, while the trial title refers to GW642444. These names appear to refer to the same investigational compound being studied for chronic obstructive pulmonary disease.